Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Repligen Corporation

Repligen Corporation (RGEN) Stock Overview

Explore Repligen Corporation’s financial performance, market position, analyst ratings, and future outlook.

RGEN●NASDAQ
HealthcareMedical - Instruments & Supplies
$192.23
$2.34(1.20%)
U.S. Market opens in 10h 53m

Repligen Corporation (RGEN)

Meyka AI Score

Z

Key Financials

Market Cap10.8B
P/E Ratio260.23
EPS (TTM)$1.80
ROE0.02%
Fundamental Analysis

AI Price Forecasts

1 Month$222.04
3 Months$175.09
1 Year Target$139.52

RGEN Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Repligen Corporation (NASDAQ: RGEN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Repligen Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RGEN on the NASDAQ shows an RSI of 67.27, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $139.52 for the NASDAQ listing.

Key metrics behind Repligen Corporation's NASDAQ-traded stock include a P/E ratio of 260.23 and a market capitalization of 10.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RGEN on the NASDAQ.

Price Performance (NASDAQ: RGEN)

1-Day Change
-1.20%
5-Day Change
1.22%
1-Month Change
9.05%
3-Month Change
40.89%
6-Month Change
72.42%
Year-to-Date (YTD) Change
17.31%
1-Year Change
43.81%
3-Year Change
24.05%
5-Year Change
-33.48%
All-Time (Max) Change
1608.71%

Contact Information

https://www.repligen.com
781 250 0111
Building 1, Waltham, MA, 02453

Company Facts

20,000 Employees
IPO DateApr 29, 1986
CountryUS
Actively Trading

Frequently Asked Questions